Major clinical research advances in gynecologic cancer 2009

Abstract

In this review, we summarized nine major clinical advances in gynecology which occurred in 2009. For cervical cancer, the role of human papillomavirus (HPV) test as a screening test, the efficacy of HPV vaccine for middle-aged women, randomized controlled trial (RCT) regarding concurrent chemoradiation using gemcitabine plus cisplatin, and the efficacy of pazopanib for metastatic or recurrent disease were chosen. For endometrial cancer, the necessity of systematic pelvic lymphadenectomy in early endometrial cancer was reviewed. For ovarian cancer, the timing of treatment initiation for recurrent ovarian cancer, dose-dense chemotherapy as postoperative adjuvant treatment, the best chemotherapy regimen for platinum-sensitive recurrent ovarian cancer, and the efficacy of target agents were selected. In addition, the results of RCT testing the benefit of ginger in preventing post-chemotherapy nausea were examined.

Correlation Between Body Mass Index and Prevalence of Hereditary Nonpolyposis Colorectal Cancer in Korean Patients With Endometrial Cancer

“…1,2 The risk factors for endometrial cancer include obesity, diabetes, late menopause, unopposed estrogen therapy, and nulliparity. 3 Inherited factors have also been suggested as important risk factors for endometrial cancer.…”

Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate‐ or high‐risk endometrioid endometrial cancer: A single institution experience

“…In the current study, we showed our experience for comparing survival and toxicity between TC and AP for CCR in patients with intermediate‐ or high‐risk endometrioid endometrial cancer. We enrolled only patients with endometrioid endometrial cancer because there were very few patients with other histological types who received CCR using TC or AP in our institute, and endometrioid adenocarcinoma is the most common endometrial cancer 2–4 . We found that TC had comparable efficacy for survival to AP for CCR with lesser hematological and non‐hematological, especially, gastrointestinal, toxicities in patients with intermediate‐ or high‐risk endometrioid endometrial cancer.…”

“…Endometrial cancer is the most common gynecologic malignancy in the USA, and its incidence has increased to approximately 16% of gynecologic cancers in Korea 1 . More than 80% of patients have International Federation of Gynecology and Obstetrics (FIGO) stages I (64%) or II (20%) of the disease 2,3 . Although most patients with low‐risk endometrial cancer may be cured after surgery, those with intermediate‐ or high‐risk endometrial cancer often show loco‐regional or distant recurrence 4 .…”

Major clinical research advances in gynecologic cancer in 2012

“…After the promising report of primary analysis [36], long-term follow-up results on PFS and OS were released in 3 years. A total of 631 patients were randomly assigned to receive c-TC (paclitaxel 180 mg/m 2 and carboplatin AUC 6 on D1) or dd-TC (paclitaxel 80 mg/m 2 on D1, 8, 15 and carboplatin AUC 6 on D1) for six cycles every 3 weeks.…”